Halozyme CEO Sells $3.2M in Stock Through Planned Trading Program

[Form 4] Halozyme Therapeutics, Inc. Insider Trading Activity

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Halozyme Therapeutics (HALO) President and CEO Helen Torley executed a series of pre-planned transactions under a Rule 10b5-1 trading plan established on March 21, 2025. The transactions occurred over three consecutive days:

June 20, 2025: Exercised 20,000 options at $8.11 and sold 20,000 shares at avg. $52.96
June 23, 2025: Exercised 20,000 options at $8.11 and sold 20,000 shares at avg. $52.57
June 24, 2025: Exercised 20,000 options at $8.11 and sold 20,000 shares (4,489 at avg. $53.11 and 15,511 at avg. $53.91)

Following these transactions, Torley holds 733,719 shares directly and 316,569 options at $8.11 strike price expiring February 3, 2026. The options were originally granted in 2016 with a 4-year vesting schedule. All transactions were executed under a pre-established 10b5-1 trading plan, demonstrating compliance with insider trading regulations.

Positive

The insider transactions were executed according to a pre-planned 10b5-1 trading plan established on March 21, 2025, indicating compliance with insider trading regulations
CEO Helen Torley still maintains a significant position of 733,719 shares after the transactions, showing continued alignment with shareholder interests
The sales were made at favorable price points between $51.94 and $54.05, significantly higher than the $8.11 exercise price, reflecting strong stock performance

Negative

CEO Helen Torley sold a total of 60,000 shares over three consecutive days (June 20-24, 2025), which could be perceived as a bearish signal by the market
The exercised options were from a 2016 grant nearing expiration (Feb 2026), suggesting the sales were more timing-driven than opportunistic
The insider's direct ownership decreased by approximately 7.5% (from 793,719 to 733,719 shares) through these transactions

Insights

Analyzing...

06/24/2025 - 05:40 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Torley Helen

(Last)

(First)

(Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO

92130

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/20/2025		M⁽¹⁾		20,000	A	$8.11	753,719	D
Common Stock	06/20/2025		S⁽¹⁾		20,000	D	$52.96⁽²⁾	733,719	D
Common Stock	06/23/2025		M⁽¹⁾		20,000	A	$8.11	753,719	D
Common Stock	06/23/2025		S⁽¹⁾		20,000	D	$52.573⁽³⁾	733,719	D
Common Stock	06/24/2025		M⁽¹⁾		20,000	A	$8.11	753,719	D
Common Stock	06/24/2025		S⁽¹⁾		4,489	D	$53.109⁽⁴⁾	749,230	D
Common Stock	06/24/2025		S⁽¹⁾		15,511	D	$53.911⁽⁵⁾	733,719	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option to Purchase Common Stock	$8.11	06/20/2025		M⁽¹⁾			20,000	⁽⁶⁾	02/03/2026	Common Stock	20,000	$8.11	356,569	D
Option to Purchase Common Stock	$8.11	06/23/2025		M⁽¹⁾			20,000	⁽⁶⁾	02/03/2026	Common Stock	20,000	$8.11	336,569	D
Option to Purchase Common Stock	$8.11	06/24/2025		M⁽¹⁾			20,000	⁽⁶⁾	02/03/2026	Common Stock	20,000	$8.11	316,569	D

Explanation of Responses:

1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1.

2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $52.71 to $53.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $51.94 to $52.87. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $52.64 to $53.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $53.65 to $54.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

6. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016.

	/s/ James R. Oehler, Attorney-in-Fact	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many HALO shares did CEO Helen Torley sell in June 2025?

CEO Helen Torley sold a total of 60,000 shares of HALO common stock across three days: 20,000 shares on June 20, 20,000 shares on June 23, and 20,000 shares on June 24, 2025. The sales were executed at prices ranging from approximately $52 to $54 per share.

What was the price range of HALO stock sales by CEO Helen Torley on June 24, 2025?

On June 24, 2025, CEO Helen Torley sold HALO shares in two tranches: 4,489 shares at prices ranging from $52.64 to $53.63 (weighted average $53.109) and 15,511 shares at prices ranging from $53.65 to $54.05 (weighted average $53.911).

How many HALO shares does CEO Helen Torley own after the June 2025 transactions?

After the reported transactions, CEO Helen Torley directly owns 733,719 shares of HALO common stock. She also holds 316,569 stock options exercisable at $8.11 per share that expire on February 3, 2026.

Was HALO CEO Helen Torley's stock sale planned in advance?

Yes, the options exercises and stock sales were made pursuant to a Rule 10b5-1 written trading plan that CEO Helen Torley adopted on March 21, 2025. This type of plan allows executives to preset future trades to avoid insider trading concerns.

What is the exercise price of HALO stock options sold by CEO Helen Torley?

CEO Helen Torley exercised stock options with a strike price of $8.11 per share. These options were originally granted on February 3, 2016, with a 4-year vesting schedule of 25% after 12 months and 1/48th monthly thereafter.

AG真人官方

[Form 4] Halozyme Therapeutics, Inc. Insider Trading Activity

Insights

FAQ

How many HALO shares did CEO Helen Torley sell in June 2025?

What was the price range of HALO stock sales by CEO Helen Torley on June 24, 2025?

How many HALO shares does CEO Helen Torley own after the June 2025 transactions?

Was HALO CEO Helen Torley's stock sale planned in advance?

What is the exercise price of HALO stock options sold by CEO Helen Torley?

NASDAQ:HALO

HALO Rankings

HALO Latest News

HALO Latest SEC Filings

HALO Stock Data

AG真人官方

Trending News

[Form 4] Halozyme Therapeutics, Inc. Insider Trading Activity

Insights

FAQ

How many HALO shares did CEO Helen Torley sell in June 2025?

What was the price range of HALO stock sales by CEO Helen Torley on June 24, 2025?

How many HALO shares does CEO Helen Torley own after the June 2025 transactions?

Was HALO CEO Helen Torley's stock sale planned in advance?

What is the exercise price of HALO stock options sold by CEO Helen Torley?

NASDAQ:HALO

HALO Rankings

HALO Latest News

HALO Latest SEC Filings

HALO Stock Data